EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization

Mengqi Yu, Tingting Yang, Shuyi Ding, Yongxian Hu iD

American Journal of Hematology · 2026-02 · 101 (2) · 318-336

DOI: 10.1002/ajh.70131 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 08.11.2025. Verfasst von Mengqi Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: Science and Technology Program for Medicine and Health in Zhejiang Province (General Program), National Natural Science Foundation of China, Zhejiang Province Vanguard Geese Leading Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable clinical efficacy in treating hematological malignancies. Nevertheless, the limited persistence of CAR‐T cells in vivo remains a major therapeutic hurdle, leading to disease relapse. This review examines current strategies to enhance CAR‐T cell durability, focusing on recent advances in CAR structural design, gene editing techniques, ex vivo culture optimization, clinical management approaches, and in vivo preparation. By integrating insights from preclinical studies and clinical trials, we provide a comprehensive analysis of methods to prolong CAR‐T cell persistence from a technical perspective and discuss future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansGene EditingAnimalsClinical Trials as Topic

Stichwörter der Autor:innen

T cellchimeric antigen receptorhematologic malignancy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.
  • Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China.

ORCID-Profile: Yongxian Hu

Förderung

  • Science and Technology Program for Medicine and Health in Zhejiang Province (General Program)
  • National Natural Science Foundation of China
  • Zhejiang Province Vanguard Geese Leading Plan Project

Zitieren

APA

Yu, M., Yang, T., Ding, S., & Hu, Y. (2026). Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization. American Journal of Hematology, 101(2), 318-336. https://doi.org/10.1002/ajh.70131

Vancouver

Yu M, Yang T, Ding S, Hu Y. Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization. American Journal of Hematology. 2026;101(2):318-336. doi:10.1002/ajh.70131

BibTeX
@article{Yu2026,
  author = {Yu, Mengqi and Yang, Tingting and Ding, Shuyi and Hu, Yongxian},
  title = {Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {2},
  pages = {318--336},
  doi = {10.1002/ajh.70131}
}
Kostenlos starten →